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We describe a transcriptional mechanism regulating the expression of Dnmt1 by nuclear receptors.
We show that ERRc functions as a transcriptional activator of mouse and human Dnmt1 expression
by direct binding to its response elements (ERE1/ERE2) in the dnmt1/DNMT1 promoters. The induc-
tion of Dnmt1 by ERRc is repressed by SHP through SHP inhibition of ERRc transactivity, diminish-
ing ERRc recruitment to the Dnmt1 promoter, and altering the conformation of local chromatin
from an active mode by ERRc to an inactive mode. Our study provides the ﬁrst evidence for nuclear
receptor mediated regulation of Dnmt1 expression through ERRc and SHP crosstalk.
Structured summary of protein interactions:
ERR gamma physically interacts with SHP by anti tag coimmunoprecipitation (View interaction).
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
DNA cytosine-5-methyltransferases (Dnmts) catalyze the
methyl transfer from S-adenosyl-L-methionine to the cytosine in
CpG dinucleotides [1]. Gene silencing due to DNA hypermethyla-
tion of promoter regions is mainly controlled by three Dnmts
(Dnmt1, Dnmt3a and Dnmt3b) [2]. Increased Dnmt expression
has been reported in several human cancers, including human
hepatocellular carcinoma (HCC) [3]. Despite evidence for their crit-
ical roles in carcinogenesis, limited information is available regard-
ing how the expression of Dnmts are transcriptionally regulated
[4–7]. Understanding the molecular mechanisms controlling Dnmt
expression is essential for learning how changes in DNA methyla-
tion result in or predispose to the development of liver cancer.
Nuclear receptor small heterodimer partner (SHP, NROB2) is a
transcriptional regulator of a number of genes that play critical
roles in hepatic lipid metabolism [8–12]. Our recent studies show
that SHP functions as a tumor suppressor in HCC. Deletion of the
SHP gene promotes spontaneous hepatoma formation in mice
due to hepatocyte hyperproliferation [13] and decreased apoptosis
[14], and SHP expression is diminished in HCC in humans due to
promoter hypermethylation [15]. These studies provide strong evi-
dence for a critical role of SHP in hepatocarcinogenesis.
In this report, we characterized a novel nuclear receptor-medi-
ated mechanism regulating the transcription of Dnmt1. We show
that SHP is a transcriptional repressor of Dnmt1 expression via
crosstalk with estrogen related receptor gamma (ERRc). This ischemical Societies. Published by Ethe ﬁrst report demonstrating that the expression of Dnmt1 is con-
trolled by nuclear receptor signaling.2. Materials and methods
2.1. Cell lines and liver biospecimens
Human cervix adenocarcinoma cells (Hela; ATCC CCL-2), human
hepatoma cells (Huh7; Health Science Research Resources Bank
JCRB0403), and mouse liver cells (Nmuli; ATCC CRL-1638) were
maintained as described previously [14,16]. Liver fragments from
ERRc+/+ and liver speciﬁc ERRc/ mice were obtained from Dr.
Ronald Evans’s laboratory.
2.2. Antibodies and siRNAs
Antibodies used in immunoprecipitation, ChIP and immunoblot
analyses include M-280 sheep anti-rabbit or mouse IgG Dynabeads
(Invitrogen Dynal As), rabbit normal IgG (Sigma, R-2004) and anti-
bodies against Flag (Sigma, F-7425), GFP (Sigma, G-1544), histone
H3 acetyl antibody (H3Ac) (Millipore, #06-599), histone H4 acetyl
antibody (H4Ac) (Millipore, #06-866), histone H3 dimethyl Lys4
antibody (H3K4Me2) (Millipore, #07-030), histone H3 dimethyl
Lys9 antibody (H3K9Me2) (Millipore, #17-648), ERRc (Sigma, AV-
31655), and DNMT1 (Cell signaling, #5032). ERRc RNAi(PDSIRNA
SASI-Hs01-00042292, SASI-Hs01-00042292-AS) and non-speciﬁc
RNAi (SIC001) were purchased from Sigma. Co-immunoprecipita-
tion (Co-IP) and Western blots (WB) were performed as described
previously [14,16].lsevier B.V. All rights reserved.
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The method are provided in our recent publications [14,16,17].
HPRT1 was used as internal control for Dnmt1 mRNA expression.
The primer sequences are: forward 50-CCCCTGAGCCCTACCGAAT-
30 and reverse 50-CTCGCTGGAGTGGACTTGTG-30 for DNMT1;
forward 50-CCGGTCTCTTTCGTTTGAGG-30 and reverse 50-CATCCTGA
AGCTTCTGAACGG-30 for hERRc; forward 50-TGACACTGGCAAAA-
CAATGCA-30 and reverse 50-GGTCCTTTTCACCAGCAAGCT-30 for
hHRPT1; forward 50-CCCAGGGCTTTCCAGATAGC-30 and reverseFig. 1. SHP inhibition of dnmt1 promoter activity by ERRc. (A) Transient transfection ass
(50, 200 ng), GR (50, 200 ng), HNF4a (50, 200 ng), ERRc (50, 200 ng), LRH-1 (50, 200 ng),
dnmt1 promoter luciferase activity by co-expression of ERRc and SHP in Hela (B) (ERRc:
ERRc + SHP: 400 ng + 100 ng), and Nmuli cells (D) (SHP: 100, 200, 400, 800 ng; ERRc:
showing the location of EREs in the dnmt1 promoter and its deletion constructs. Right: Tr
(100 ng) in Hela cells. (A–E) The luciferase activities were normalized by renilla activities
The experiments were repeated three times (triplicate wells/time) with similar results. O
(WB) to determine the direct association of SHP with the ERRc protein. Hela cells wer
expression vectors. Anti-Flag antibodies were used to immunoprecipitate ERRc, and the
antibodies, respectively.50-AACT GCAGCTGATGCGCTC-30 for dnmt1; forward 50-CAC-
CTGCATCTCACAGCCACT-30 and reverse 50-GCCAACCCAAGCAGGA-
AGA-30 for mSHP; and forward 50-CGTCGTGATTAGCGATGATGA-30
and reverse 50-CACACAGA GGGCCACAATGT-30 for mHPRT1.
2.4. Transient transfection and promoter activity assays
Detailed methods can be found in our recent publications
[14,16,18–21]. The mouse dnmt1 (Gene ID: 13433) promoter and
its deletion mutation luciferase constructs (mdnmt1 Luc) wereays to determine dnmt1 promoter luciferase (luc) activity (act) by expression of ERa
or RXRa (50, 200 ng) in Hela cells. (B-D) Transient transfection assays to determine
50, 200 ng; SHP, 200 ng; ERRc + SHP, 200 ng + 200 ng), Huh7 (C) (ERRc: 100, 400 ng;
200, 400, 800 ng; ERRc + SHP: 800 ng + 200 ng, 800 ng + 400 ng). (E) Left: Diagram
ansient transfection assays to determine dnmt1 promoter lucifease activity by ERRc
. Data is represented as mean ± S.E.M. (⁄P < 0.01 vs. control; ¥P < 0.01 vs. ERRc alone).
ne representative result is shown. (F) Immunoprecipitation (IP) and Western blots
e transfected with Flag-ERRc (1 lg, 3 cm plate) and/or GFP-SHP (1 lg, 3 cm plate)
protein levels of SHP and ERRc were detected by WB using anti-GFP or anti-Flag
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ously [16].
2.5. ChIP and ChIP-ReChIP assays
Chromatin immunoprecipitation (ChIP) assays were done as de-
scribed previously [14,16]. To analyze the reciprocal association
between ERRc and SHP immunoprecipitates, ﬁrst ChIP was per-
formed with antibody against Flag, washed, and the bound im-
mune-DNA complexes were released in 50 ll of elution buffer
(1X TE containing 2% SDS, 15 mM DTT and protease inhibitors)
for 30 min at 37 C and resuspended in 30 times volume of IP dilu-Fig. 2. SHP inhibition of ERRc recruitment to the Dnmt1 promoter. (A) Schematic showin
C) ChIP assays to determine ERRc and SHP co-immunoprecipitation (Co-IP) to the ERE
expressed in Hela cells with Flag-ERRc (5 lg, 10 cm plate) and/or GFP-SHP (5 lg, 1
immunoprecipitated using anti-Flag or anti-GFP antibodies. Real-time qPCR was used to
mP1 and mP2 primers (B), and their association to the endogenous DNMT1 promoter wa
positive controls, IgG-negative controls, and antibody immunoprecipitates. Histograms
Relative (Rel) enrichment. Error bars represent S.E.M. from three independent measuremtion buffer (Tris pH 8.0 50 mM, EDTA 5 mM, NaCl 200 mM, NP40
0.5%) for ReChIP with antibody to GFP. Real-time qPCR was per-
formed using ChIP primer sets speciﬁc for the ERRc binding sites
in the dnmt1 and DNMT1 promoters: mouse p1 forward 50-
CTGGCTTTCTCTGTGTGGCTC-30 and reverse 50-CATGCCTGC
AGTCCCTTACAC-30, mouse p2 forward 50-CAAGACCAGAGAGAGG-
CAGGA-30 and reverse 50-CCACATCCAGCCACTCGAA-30; human p1
forward 50-TGAGCCGTAGTGACCCACCTA-30 and reverse 50-GGGA-
TAAAGCAGCGAGAAGCC-30, human p2 forward 50-GTTTGGAC-
TATGGGCACATGC-30 and reverse 50-CGCTTGAGCCCAGGAGTTT-30.
A control region from 1489 to 1310 in dnmt1 promoter
(forward 50-CTGAGCCATCTCTCCATCC-30 and reverse 50-CCGAG-g the putative ERRc binding sites (EREs) in the dnmt1 and DNMT1 promoters. (B and
region of the dnmt1 (B) or DNMT1 (C) promoter. ERRc and SHP were exogenously
0 cm plate) plasmids, along with the dnmt1 promoter. The chromatin was co-
determine the association of ERRc and SHP to the exogenous dnmt1 promoter using
s determined by hP1 and hP2 primers (C). PCR products were ampliﬁed from input-
show antibody/input ratios of PCR products quantiﬁed using qPCR, expressed as
ents.
Fig. 3. Co-recruitment of ERRc and SHP to the Dnmt1 promoter. (A–D) ChIP-ReChIP analysis by PCR (A and C) or qPCR (B and D) to illustrate the enrichment of ERRc and SHP
to the dnmt1 (A–B) or DNMT1 (C–D) promoter. Soluble chromatin was prepared and immunoprecipitated (1 ChIP) with anti-Flag antibodies. Immunocomplexes were
collected and eluted, and soluble chromatin fraction was reimmunoprecipitated (2 ReChIP) with anti-GFP antibodies. Other procedures were done as described in Fig. 2. (E)
ChIP assays by PCR (left and middle) and q-PCR (right) to determine ERRc recruitment to the endogenous DNMT1 promoter in Hela cells with ERRc knockdown using siRNA
(ERRcRNAi, 100 pmol). ChIP analysis was done as described in Fig. 2.
Fig. 4. Alteration of histone modiﬁcations of the dnmt1 promoter by ERRc and SHP.
The chromatin was co-immunoprecipitated using anti-H3Ac, anti-H4Ac, anti-
H3K4Me2 or anti-H3K9Me2 antibodies. ChIP analysis was done as described in
Fig. 2. ⁄P < 0.01 vs. pcDNA control; ¥P < 0.01 vs. ERRc group.
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(forward 50-TTCTGGCTGGTTACGGTGG-30 and reverse 50-CAT-
GTTGGCCAGGCTAGTCTG-30) serves as negative control.
2.6. Statistical analysis
Data are expressed as mean ± S.E.M. Statistical analyses were
carried out using Student’s unpaired t test; P < 0.01 was considered
statistically signiﬁcant.
3. Results
3.1. SHP inhibits ERRc transactivation of the dnmt1 promoter
Putative binding elements for nuclear receptors estrogen recep-
tor alpha (ERa), glucocorticoid receptor (GR), hepatocyte nuclear
factor 4a (HNF4a), ERRc, liver receptor homologue 1 (LRH-1),
and retinoid X receptor alpha (RXRa) were predicted in the mouse
dnmt1 promoter. We cloned a 1.5 kb proximal promoter of dnmt1
into a luciferase (luc) reporter. ERRc, but not ERa, GR, HNF4a, LRH-
1, and RXRa, markedly activated the dnmt1 promoter dose-depen-
dently (Fig. 1A). SHP was previously shown to interact with and in-
hibit ERRc transactivation [10,22]. As expected, co-expression of
SHP sufﬁciently abrogated the activity of ERRc (Fig. 1B). Similar
but less striking results were observed in human Huh7 (Fig. 1C)
and in mouse Nmuli (Fig. 1D) cells. Two putative ERE sites were lo-
cated in the dnmt1 promoter (Fig. 1E, left). We generated two mu-
tant (mut) dnmt1 luc constructs (mutLuc 798 and 628). Althoughthe basal luciferase activity of each mutant promoter was different,
single deletion of ERE2 (798) or double deletion of ERE2/ERE1
(628) markedly attenuated dnmt1 promoter activation by ERRc
(Fig. 1E, right). The data suggest that both ERE sites may be func-
tional for ERRc binding. We also conﬁrmed the physical association
of SHP with the ERRc protein in Hela cells using Co-IP and WB
(Fig. 1F).
3.2. SHP decreases ERRc recruitment to the Dnmt1 promoter
Putative ERE sites were also located in the human DNMT1 pro-
moter (Fig. 2A). ChIP analysis revealed that ERRc had an approxi-
mately 4 fold higher afﬁnity with mERE1 than with mERE2 in the
dnmt1 promoter, which was markedly diminished by SHP co-
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stronger as compared to mERE2 (Fig. 2B, right). The physical asso-
ciation of ERRc and SHP with the endogenous DNMT1 promoter
was examined. Similar to what was observed with the dnmt1 pro-
moter, ERRc bound preferentially to hERE1 than to hERE2, which
was abrogated by SHP (Fig. 2C, left). In addition, SHP exhibited
favorable binding to hERE1 than to hERE2 (Fig. 2C, right) in the
DNMT1 promoter.
We performed primary ChIP followed by a secondary immuno-
precipitation (ReChIP) to determine whether ERRc and SHP were
enriched on similar ERE region of the dnmt1/DNMT1 promoter orFig. 5. SHP inhibition of Dnmt1 expression through ERRc. (A) qPCR analysis of DNMT1 (le
6 cm plate) and/or SHP (3 lg, 6 cm plate) expression vectors. Right: WB analysis of ERRc
(0, 0.5, 1 lg, 12 well plate). Anti-ERRc and anti-GFP antibodies were used, respectively. (
Flag-ERRc and GFP-SHP plasmids. The protein levels of ERRc and SHP in the whole cell ly
GFP antibodies, respectively. PARP was used as a marker for nuclear proteins and a-tubu
hepatic dnmt1 and SHP mRNA in liver speciﬁc ERRc-knockout (ERRc/)mice. (D) qPCR a
(, non-speciﬁc siRNA control; +, 100 pmol ERRcRNAi; ++, 200 pmol ERRcRNAi). (A, C an
⁄P < 0.01 vs. control; ¥P < 0.01 vs. ERRc alone. Rel, relative. (E) WB analysis of DNMT1 and
control; +, 100 pmol ERRcRNAi). Anti-DNMT1 and anti-ERRc antibodies were used, resp
ERRc overexpression (0, 1, 4 lg, 6 cm plate). Anti-DNMT1 and anti-Flag antibodies werewhether the two receptors were recruited independently of each
other. Consistent with the results in Fig. 2, ChIP analysis revealed
a stronger binding of ERRc to mERE1/hERE1 than to mERE2/hERE2
by both PCR (Figs. 3A and C and 1 ChIP vs. Input) and q-PCR (Fig. 3B
and D, left). The ReChIP experiments showed binding of SHP on
ERRc immunoprecipitates (Figs. 3A and 3C and 2 ReChIP; Fig. 3B
and D, right).
To further validate the ﬁnding that ERRc binding was speciﬁc to
the DNMT1 promoter, ERRc-siRNA was used to knockdown the
endogenous ERRc in Hela cells. The enrichment of ERRc to hERE1
and hERE2 was markedly reduced by ERRcRNAi (Fig. 3E).ft) and ERRc (middle) mRNA in Hela cells that were overexpressed with ERRc (3 lg,
and GFP-SHP protein in Hela cells that were overexpressed with GFP-SHP plasmids
B) WB analysis of ERRc and SHP protein in Hela cells that were overexpressed with
sate, nuclear fraction and cytosolic fraction were detected using anti-Flag and anti-
lin was used as a marker for whole cell and cytosolic proteins. (C) qPCR analysis of
nalysis of ERRc and DNMT1 mRNA in Hela cells with ERRc knockdown using siRNA
d D) Data are represented as mean ± S.E.M. of three independent assays (n = three).
ERRc protein in Hela cells with ERRc knockdown using siRNA (, non-speciﬁc siRNA
ectively. (F) WB analysis of DNMT1 and Flag-ERRc protein in Hela cells with Flag-
used, respectively. A weak non-speciﬁc band was seen in the ﬁrst lane.
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by ERRc
Gene expression could be regulated by epigenetic modiﬁcation
and more particularly by posttranslational modiﬁcation of histones
[23]. We examined histone modiﬁcations in the dnmt1 promoter
by ERRc and SHP using antibodies speciﬁc to transcriptionally ac-
tive (H3Ac, H4Ac, and H3K4Me2) and inactive (H3K9Me2) histone
marks [24]. We observed a marked increase in dnmt1 promoter
occupancy by ERRc, as indicated by the increased levels of H3Ac
and H3K4Me2 and decreased levels of H3K9Me2 (Fig. 4). ERRc
did not alter H4Ac occupancy in the dnmt1 promoter. On the con-
trary, SHP co-expression reversed the effect of ERRc by decreasing
H3K4Me2 and increasing H3K9Me2. SHP also markedly decreased
H3Ac and H4Ac occupancy in the dnmt1 promoter. The results sug-
gest that ERRc results in transcriptionally active conﬁguration of
the dnmt1 promoter which is inhibited by SHP.
3.4. SHP inhibits ERRc induction of Dnmt1 expression
The endogenous DNMT1 mRNA was induced by ERRc which
was down-regulated by SHP (Fig. 5A, left). Interestingly, SHP also
decreased the endogenous ERRc mRNA (Fig. 5A, middle) to unde-
tectable levels, suggesting that SHP may counteract the effect of
ERRc by repressing ERRc gene expression, in addition to interact-
ing with ERRc to repress the transactivation of its target gene
[22]. ERRc protein was not completely repressed by SHP (Fig. 5A,
right) compared to its mRNA, suggesting that a post-translational
mechanism may be involved in regulating ERRc protein stability.
The levels of exogenously expressed ERRc protein were not
inhibited by SHP co-expression (Fig. 5B), conﬁrming that the SHP
inhibition of ERRc activity in Fig. 1 represents the effect of a direct
protein-protein interaction between ERRc and SHP. The mRNA of
dnmt1 was moderately but not signiﬁcantly decreased in liver of
ERRc/ mice (Fig. 5C, left). SHP can be constitutively activated
by ERRc [22] and SHP mRNA was markedly decreased in ERRc/
mice (Fig. 5C, right). The reduced SHP expression may result in a
derepression of Dnmt1 therefore mask the lost activation of ERRc
on dnmt1. ERRc knockdown using siRNA reduced the levels of
DNMT1 mRNA (Fig. 5D) and protein (Fig. 5E), whereas ERRc over-
expression increased DNMT1 protein (Fig. 5F). These results fur-
ther suggest a crosstalk between ERRc and SHP in regulating the
expression of dnmt1 and DNMT1.4. Discussion
Previous work has shown that the dnmt1 promoter of mouse is
independently activated by Sp1/Sp3 [4] and E2F [5,25] transcrip-
tion factors, and that human DNMT1 is activated by STAT3 [7]. A
recent study demonstrated that p53 is a negative regulator of
Dnmt1 promoter activity [26]. However, no information is avail-
able whether Dnmt1 gene transcription is regulated by nuclear
receptors.
In this study, we identiﬁed nuclear receptor SHP as a transcrip-
tional repressor of both mouse dnmt1 and human DNMT1 expres-
sion by inhibiting the activity of ERRc. Such regulation was
observed in several cancer cell lines including Hela and Huh7 cells,
but was stronger in Hela cells, suggesting that this regulatory
mechanism may play an important role in controlling DNMT1
function in cervical cancer. However, it should be noted that the
expression of Dnmt1 was only partially decreased by ERRc knock-
down, indicating that in addition to the ERRc/SHP pathway, other
mechanisms may exist to control the expression of Dnmt1.
Another observation was that the ERRc protein was moderately
repressed by SHP, which is distinct from the complete repression ofits mRNA by SHP. We also observed that SHP overexpression itself
did not inhibit DNMT1 mRNA and protein (not shown) in Hela
cells. This could be in part attributed to the moderate inhibitory ef-
fect of SHP on the ERRc protein. Nevertheless, our results provide
strong evidence for a novel role of SHP in repressing gene tran-
scription of Dnmt1 via ERRc.
Importantly, the co-recruitment of SHP with ERRc to the
dnmt1/DNMT1 promoters signiﬁcantly decreased the enrichment
of ERRc. In addition, binding of ERRc to the dnmt1 promoter in-
duces transcriptionally active conﬁguration of the promoter, which
is reversed by co-expression of SHP. This suggests that the major
mechanism for SHP inhibition of dnmt1 promoter activity is
through alteration of local chromatin structure by ERRc. SHP-med-
iated repression is not limited to the action of ERRc, because SHP
also decreases H4Ac occupancy which is not signiﬁcantly affected
by ERRc. The results suggest that SHP may have a general function
to keep the local chromatin conﬁguration of its target genes in a
repressive mode, which is consistent with its role as a universal
transcriptional repressor [27].
Over sixty chromatin modifying enzymes have been identiﬁed
[28,29], and many of them are associated with post-translational
modiﬁcation of H3Ac, H4Ac, H3K4Me2, and H3K9Me2. It remains
to be determined in future studies whether SHP and ERRc are
co-recruited to a multiprotein complex including proteins govern-
ing the post-translational modiﬁcation of histones, and how this
would regulate the gene transcription of Dnmt1.
Overall, our ﬁndings are important because they link SHP func-
tion to DNA methylation at the molecular levels. Considering the
importance of Dnmt1 in DNA methylation associated silencing of
tumor suppressors [2], and the critical role of SHP in liver cancer
progression [13–15], the identiﬁcation of the regulatory role of
SHP in controlling Dnmt1 expression improves our understanding
of the epigenetic mechanisms governing the development of liver
cancer.
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